New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export TMO’s income statement to Excel — free account
Thermo Fisher Scientific Inc.
TMOHealthcare Diagnostics & Research
Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.
- Revenue
- +9.13%
- EPS
- +8.67%
- Free cash flow
- +15.0%
- Total debt
- +22.8%
Quarter to September 2026, against a year earlier
670.06
18.69
−2.71%
After hours trading: 673.50, up 0.51%, last trade Fri 6:42pm Eastern.
Follow TMO
Alert me
Revenue to profit Q3 FY2026, quarter to Sep 30, 2026
Of every $100 of revenue, $14.23 was left as profit. Gross margin has risen two quarters running, from 40.3% to 42.3%. What is an income statement?
| Revenue | 12.1 | 100.0% |
|---|---|---|
| Cost of revenue | −7.0 | −57.7% |
| Gross profit | 5.1 | 42.3% |
| Research & development | −0.3 | −2.9% |
| Selling, general & admin | −2.3 | −19.1% |
| Other operating costs | −0.2 | −1.6% |
| Operating income | 2.3 | 18.6% |
| Other income, net | −0.2 | −1.4% |
| Income tax | −0.4 | −2.9% |
| Net income | 1.7 | 14.2% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $12.2B | $11.0B | $12.0B | $12.1B |
| Operating income | $2.3B | $1.9B | $2.1B | $2.3B |
| Net income | $2.0B | $1.7B | $1.7B | $1.7B |
| Net margin (right axis) | 16.1% | 15.0% | 14.5% | 14.2% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
12,137.00 | 11,994.00 | 11,005.00 | 12,215.00 |
+8 more quarters Free account |
Revenue Growth |
9.13% | 10.49% | 6.18% | 7.20% | |
Cost of Revenue |
7,006.00 | 7,112.00 | 6,575.00 | 7,204.00 | |
Gross Profit |
5,131.00 | 4,882.00 | 4,430.00 | 5,011.00 | |
R&D Expenses |
348.00 | 364.00 | 336.00 | 357.00 | |
SG&A Expenses |
2,321.00 | 2,333.00 | 2,181.00 | 2,352.00 | |
Operating Income |
2,263.00 | 2,087.00 | 1,864.00 | 2,255.00 | |
Non-operating Interest Expenses |
417.00 | 401.00 | 354.00 | 365.00 | |
Non-operating Income/Expense |
(175.00) | (163.00) | (130.00) | (100.00) | |
| 2,088.00 | 1,924.00 | 1,734.00 | 2,153.00 | ||
Income Tax Provision |
352.00 | 167.00 | 70.00 | 153.00 | |
Income after Tax |
1,736.00 | 1,757.00 | 1,664.00 | 2,000.00 | |
Share of Subsidiary Earnings |
(9.00) | (15.00) | (8.00) | (31.00) | |
Dividends (Preferred) |
— | — | — | 1.00 | |
Non-Controlling Interest |
6.00 | 5.00 | 5.00 | 6.00 | |
Net Income Common |
1,721.00 | 1,736.00 | 1,651.00 | 1,964.00 | |
EPS (Basic) |
4.65 | 4.68 | 4.44 | 5.22 | |
EPS (Diluted) |
4.64 | 4.68 | 4.43 | 5.21 | |
Shares (Basic, Weighted) |
370.00 | 371.00 | 372.00 | 377.00 | |
Shares (Diluted, Weighted) |
371.00 | 371.00 | 373.00 | 378.00 | |
Gross Margin |
42.28% | 40.70% | 40.25% | 41.02% | |
EBIT Margin |
18.65% | 17.40% | 16.94% | 18.46% | |
EBT margin |
17.20% | 16.04% | 15.76% | 17.63% | |
Net Profit Margin |
14.18% | 14.47% | 15.00% | 16.08% | |
EBITDA |
3,088.00 | 2,904.00 | 2,600.00 | 2,983.00 | |
EBIT |
2,263.00 | 2,087.00 | 1,864.00 | 2,255.00 | |
Income from Continuous Operations |
1,727.00 | 1,742.00 | 1,656.00 | 1,969.00 | |
Consolidated Net Income/Loss |
1,727.00 | 1,741.00 | 1,656.00 | 1,971.00 | |
EPS (Basic, from Continuous Ops) |
4.67 | 4.70 | 4.45 | 5.26 | |
EPS (Diluted, from Cont. Ops) |
4.66 | 4.70 | 4.44 | 5.22 | |
EPS (Basic, Consolidated) |
4.67 | 4.69 | 4.45 | 5.26 | |
EPS (Diluted, Consolidated) |
4.66 | 4.69 | 4.44 | 5.22 | |
Shares (Diluted, Average) |
371.00 | 371.00 | 373.00 | 377.00 | |
EBITDA Margin |
25.44% | 24.21% | 23.63% | 24.42% | |
Operating Cash Flow Margin |
21.01% | 17.72% | 10.83% | 28.30% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026